Effects of ipsapirone and cannabidiol on human experimental anxiety
Abstract
The effects of ipsapirone and cannabidiol (CBD) on healthy volunteers submitted to a simulated public speaking (SPS) test were compared with those of the anxiolytic benzodiazepine diazepam and placebo. Four independent groups of 10 subjects received, under a double-blind design, placebo or one of the following drugs: CBD (300 mg), diazepam (10 mg) or ipsapirone (5 mg). Subjective anxiety was evaluated through the Visual Analogue Mood Scale (VAMS) and the State-trait Anxiety Inventory (STAI). The VAMS anxiety factor showed that ipsapirone attenuated SPS-induced anxiety while CBD decreased anxiety after the SPS test. Diazepam, on the other hand, was anxiolytic before and after the SPS test, but had no effect on the increase in anxiety induced by the speech test. Only ipsapirone attenuated the increase in systolic blood pressure induced by the test. Significant sedative effects were only observed with diazepam. The results suggest that ipsapirone and CBD have anxiolytic properties in human volunteers submitted to a stressful situation.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In human studies, the anxiolytic effects of CBD have been elicited in subjects submitted to the SPST.
“In human studies, the anxiolytic effects of CBD have been elicited in subjects submitted to the Simulation Public Speaking Test (SPST) (Zuardi et al, 1993).”
From Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients (2011) · cites this paper as Zuardi et al, 1993
Acute anxiolytic effects of CBD have been observed in healthy controls with doses ranging from 300 to 600 mg.
“acute anxiolytic effects of CBD have been observed in healthy controls with doses ranging from 300 (Zuardi et al, 1993) to 600 mg (Fusar-Poli et al, 2009a, 2009b).”
From Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients (2011) · cites this paper as Zuardi et al, 1993
A factorial analysis of the Portuguese version of VAMS yielded four factors with similar item composition to the original.
“A factorial analysis performed with the Portuguese version of the VAMS also yielded four factors with similar item composition (Zuardi et al, 1993).”
From Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients (2011) · cites this paper as Zuardi et al, 1993
CBD reverses glossophobia (fear of public speaking).
“and glossophobia (fear of public speaking) (Bergamaschi et al., 2011; Crippa et al., 2004; Zuardi et al., 1993)”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Zuardi et al., 1993
Cites
(1970) · Cited by 24,983 · see citing works
Structure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011 · see citing works
Manual for the Wechsler Adult Intelligence Scale.
Wechsler, D. (1955) · Psychological Corp. eBooks · Cited by 4,941 · see citing works
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · see citing works
The use of analogue scales in rating subjective feelings
BOND, A., & LADER, M. (1974) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1974.tb02285.x · Cited by 1,972 · see citing works
The development of a scale to measure fear
Geer, J. H. (1965) · Behaviour Research and Therapy · doi:10.1016/0005-7967(65)90040-9 · Cited by 777 · see citing works
Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects
Zuardi, A. W., Shirakawa, I., Finkelfarb, E., & Karniol, I. G. (1982) · Psychopharmacology · doi:10.1007/bf00432554 · Cited by 608 · see citing works
Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients
Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R. J., Sanvito, W. L., Lander, N., & Mechoulam, R. (2008) · Pharmacology · doi:10.1159/000137430 · Cited by 570 · see citing works
The action of sedatives on brain stem oculomotor systems in man
Norris, H. (1971) · Neuropharmacology · doi:10.1016/0028-3908(71)90039-6 · Cited by 388 · see citing works
Pertwee, R. G. (1977) · Neuroscience · doi:10.1016/0306-4522(77)90080-x · Cited by 384 · see citing works
Antianxiety effect of cannabidiol in the elevated plus-maze
Guimarães, F. S., Chiaretti, T. M., Graeff, F. G., & Zuardi, A. W. (1990) · Psychopharmacology · doi:10.1007/bf02244012 · Cited by 379 · see citing works
Goa, K. L., & Ward, A. (1986) · Drugs · doi:10.2165/00003495-198632020-00002 · Cited by 334 · see citing works
Controlled clinical trial of cannabidiol in Huntington's disease
Consroe, P. F., Laguna, J., Allender, J. R., Snider, S. R., Stern, L. Z., Sandyk, R., Kennedy, K., & Schram, K. H. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90386-g · Cited by 324 · see citing works
Pharmacological characterization of cannabinoids in the elevated plus maze.
Onaivi, E. S., Green, M. R., & Martin, B. R. (1990) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)13195-9 · Cited by 312 · see citing works
Cannabidiol interferes with the effects of Δ9-tetrahydrocannabinol in man
Karniol, I. G., Shirakawa, I., Kasinski, N., Pfeferman, A., & Carlini, E. A. (1974) · European Journal of Pharmacology · doi:10.1016/0014-2999(74)90129-0 · Cited by 303 · see citing works
Pharmacological interaction between cannabidiol and ?9-tetrahydrocannabinol
Karniol, I. G., & Carlini, E. A. (1973) · Psychopharmacology · doi:10.1007/bf00428793 · Cited by 182 · see citing works
Tyrer, P. J. (1988) · Oxford University Press eBooks · Cited by 166 · see citing works
Simulated public speaking as a model of clinical anxiety
McNair, D. M., Frankenthaler, L. M., Czerlinsky, T., White, T. W., Sasson, S., & Fisher, S. (1982) · Psychopharmacology · doi:10.1007/bf00436092 · Cited by 140 · see citing works
Agurell, S., Carlsson, S., Lindgren, J. E., Ohlsson, A., Gillespie, H., & Hollister, L. (1981) · Experientia · doi:10.1007/bf02085029 · Cited by 129 · see citing works
Intra-hippocampal buspirone in animal models of anxiety
Kostowski, W., Płaźnik, A., & Stefański, R. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90803-0 · Cited by 123 · see citing works
Influence of cannabidiol on delta‐9‐tetrahydrocannabinol effects
Dalton, W. S., Martz, R. C., Lemberger, L., Rodda, B. E., & Forney, R. B. (1976) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1976193300 · Cited by 123 · see citing works
Effect of chlorimipramine and maprotiline on experimental anxiety in humans
Guimarães, F. S., Zuardi, A. W., & Graeff, F. G. (1987) · Journal of Psychopharmacology · doi:10.1177/026988118700100305 · Cited by 110 · see citing works
Pharmacological interaction between cannabinol and ?9-tetrahydrocannabinol
Takahashi, R. N., & Karniol, I. G. (1975) · Psychopharmacology · doi:10.1007/bf00428937 · Cited by 96 · see citing works
Central Serotonin Receptors and Psychotropic Drugs
Tricklebank, M. D. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90126-7 · Cited by 88 · see citing works
Effect of metergoline on human anxiety
Graeff, F. G., Zuardi, A. W., Giglio, J. S., Filho, E. C. L., & Karniol, I. G. (1985) · Psychopharmacology · doi:10.1007/bf00432224 · Cited by 85 · see citing works
Vry, J. D., Gläser, T., Schuurman, T., Schreiber, R., & Traber, J. (1991) · doi:10.1007/978-1-349-11847-2_7 · Cited by 82 · see citing works
Carlini, E. A., Santos, M., Claussen, U., Bieniek, D., & KORTE, F. (1970) · Psychopharmacology · doi:10.1007/bf00402387 · Cited by 81 · see citing works
Gepirone in anxiety: a pilot study.
Csanalosi, I., Schweizer, E. E., CASE, W. G., & Rickels, K. (1987) · PubMed · Cited by 72 · see citing works
Intravenous Δ9-Tetrahydrocannabinol
Malit, L. A., Johnstone, R. E., Bourke, D. L., Kulp, R. A., Klein, V., & Smith, T. C. (1975) · Anesthesiology · doi:10.1097/00000542-197506000-00008 · Cited by 58 · see citing works
Teicher, M. H. (1988) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30745-3 · Cited by 56 · see citing works
Reduction in cortical 5HT2 receptor sensitivity after continuous gepirone treatment
Eison, A. S., & Yocca, F. D. (1985) · European Journal of Pharmacology · doi:10.1016/0014-2999(85)90648-x · Cited by 56 · see citing works
Nye, J. S., Seltzman, H. H., Pitt, C. G., & Snyder, S. H. (1985) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23705-3 · Cited by 54 · see citing works
Csanalosi, I., Schweizer, E. E., Rickels, K., & Case, G. W. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198702000-00006 · Cited by 50 · see citing works
Early postnatal treatment with propranolol affects development of brain amines and behavior
Hilakivi, L. A., Taira, T., Hilakivi, I. T., MacDonald, E., Tuomisto, L. M., & Hellevuo, K. (1988) · Psychopharmacology · doi:10.1007/bf00216061 · Cited by 39 · see citing works
Brain 5-HT1A receptor agonism: a novel mechanism for antihypertensive action
Saxena, P. R., & Villalón, C. M. (1990) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(90)90187-d · Cited by 31 · see citing works
Lovick, T. A. (1990) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/bf00370249 · Cited by 30 · see citing works
A simple simulated public speaking test for evaluating anxiolytic drugs.
Fs, G., Cl, K., Gus, G., Hs, F., Mc, D.-V., Cl, D.-P., Ribeiro, A. M., Cc, T., & Wannmacher, L. (1989) · PubMed · Cited by 27 · see citing works
5 ht receptor subtypes and the modulation of aversion
Deakin, J. F. W., Graeff, F. G., & Guimarães, F. S. (1992) · Cited by 24 · see citing works
5-HT Receptor Mechanisms in Human Anxiety
Deakin, J. F. W., Guimarães, F. S., Wang, M., Hellewell, J. S. E., & Hensman, R. (1991) · doi:10.1007/978-1-349-11847-2_6 · Cited by 13 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771 · see citing works
Cannabidiol as a Potential Treatment for Anxiety Disorders
Blessing, E., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0387-1 · Cited by 718 · see citing works
Bhattacharyya, S., Morrison, P. D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O' Carroll, C. M., Seal, M., Allen, P., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.184 · Cited by 680 · see citing works
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558 · see citing works
Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379283 · Cited by 535 · see citing works
Cannabidiol: An Overview of Some Pharmacological Aspects
Mechoulam, R., Parker, L. A., & Gallily, R. (2002) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.2002.tb05998.x · Cited by 511 · see citing works
Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475 · see citing works
Self-citationFusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S. A., O’Carrol, C., Atakan, Z., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.519 · Cited by 465 · see citing works
Self-citationCannabidiol, neuroprotection and neuropsychiatric disorders
Campos, A. C., Fogaça, M. V., Sonego, A. B., & Guimarães, F. S. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.033 · Cited by 446 · see citing works
Cannabidiol in Anxiety and Sleep: A Large Case Series
Shannon, S. M., Lewis, N., Lee, H. J., & Hughes, S. (2019) · The Permanente Journal · doi:10.7812/tpp/18-041 · Cited by 433 · see citing works
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421 · see citing works
Cannabis and anxiety: a critical review of the evidence
Crippa, J. A., Zuardi, A. W., Martín‐Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., & Fusar‐Poli, P. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1048 · Cited by 509 · see citing works
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Moreira, F. A., & Guimarães, F. S. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000400001 · Cited by 402 · see citing works
Cannabis and adolescent brain development.
Lubman, D. I., Cheetham, A., & Yücel, M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.009 · Cited by 360 · see citing works
Hurd, Y. L., Spriggs, S. A., Alishayev, J., Winkel, G. H., Gurgov, K., Kudrich, C., Oprescu, A. M., & Salsitz, E. A. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.18101191 · Cited by 344 · see citing works
Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age
Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02009 · Cited by 308 · see citing works
Effects of cannabidiol (CBD) on regional cerebral blood flow
Crippa, J. A. D. S., Zuardi, A. W., Garrido, G. E. J., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E. C., McGuire, P. K., & Busatto, G. F. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300340 · Cited by 307 · see citing works
Cannabidiol: pharmacology and therapeutic targets
Britch, S. C., Babalonis, S., & Walsh, S. L. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05712-8 · Cited by 307 · see citing works
García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020) · Biomolecules · doi:10.3390/biom10111575 · Cited by 306 · see citing works
Role of the amygdala and periaqueductal gray in anxiety and panic.
Graeff, F. G., Silveira, M. C. L., Nogueira, R. L., Audi, E. A., & Oliveira, R. M. W. (1993) · Behavioural Brain Research · doi:10.1016/0166-4328(93)90097-a · Cited by 301 · see citing works
Self-citationMartín‐Santos, R., Crippa, J. A. S., Batalla, A., Bhattacharyya, S., Atakan, Z., Borgwardt, S., Allen, P., Seal, M. L., Langohr, K., Farré, M., et al. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884780 · Cited by 298 · see citing works
Immune Responses Regulated by Cannabidiol
Nichols, J. M., & Kaplan, B. L. F. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0073 · Cited by 297 · see citing works
A narrative review of molecular mechanism and therapeutic effect of cannabidiol (CBD)
Peng, J., Fan, M., An, C., Ni, F., Huang, W., & Luo, J. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13710 · Cited by 291 · see citing works
Fraguas‐Sánchez, A. I., & Torres‐Suárez, A. I. (2018) · Drugs · doi:10.1007/s40265-018-0996-1 · Cited by 271 · see citing works
Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial
Allsop, D. J., Copeland, J., Lintzeris, N., Dunlop, A. J., Montebello, M., Sadler, C., Rivas, G. R., Holland, R. M., Muhleisen, P., Norberg, M. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3947 · Cited by 266 · see citing works
The elevated T-maze: A new animal model of anxiety and memory
Viana, M. D. B., Tomaz, C. A. B., & Graeff, F. G. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90067-1 · Cited by 265 · see citing works
Zuardi, A. W., Rodrigues, N. P., Silva, A. L., Bernardo, S. A., Hallak, J. E. C., Guimarães, F. S., & Crippa, J. A. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00259 · Cited by 294 · see citing works
A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential
White, C. M. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1387 · Cited by 247 · see citing works
Does Cannabidiol Protect Against Adverse Psychological Effects of THC?
Niesink, R. J. M., & van Laar, M. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00130 · Cited by 241 · see citing works
The endocannabinoid system as a target for novel anxiolytic drugs
Patel, S., Hill, M. N., Cheer, J. F., Wotjak, C. T., & Holmes, A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.033 · Cited by 233 · see citing works
Cannabis and psychiatric disorders: it is not only addiction
Leweke, F. M., & Koethe, D. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00106.x · Cited by 213 · see citing works
Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test
Linares, I. M., Zuardi, A. W., Pereira, L. C., Queiroz, R. H., Mechoulam, R., Guimarães, F. S., & Crippa, J. A. (2019) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2017-0015 · Cited by 241 · see citing works
Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders
Scuderi, C., Filippis, D. D., Iuvone, T., Blasio, A., Steardo, A., & Esposito, G. (2008) · Phytotherapy Research · doi:10.1002/ptr.2625 · Cited by 209 · see citing works
Haney, M., Malcolm, R. J., Babalonis, S., Nuzzo, P. A., Cooper, Z. D., Bedi, G., Gray, K. M., McRae-Clark, A., Lofwall, M. R., Sparenborg, S., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.367 · Cited by 206 · see citing works
Cannabidiol Is a Potent Inhibitor of the Catalytic Activity of Cytochrome P450 2C19
Jiang, R., Yamaori, S., Okamoto, Y., Yamamoto, I., & Watanabe, K. (2013) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rg-129 · Cited by 199 · see citing works
Cannabidiol in Humans—The Quest for Therapeutic Targets
Zhornitsky, S., & Potvin, S. (2012) · Pharmaceuticals · doi:10.3390/ph5050529 · Cited by 199 · see citing works
Anxiolytic Effects of Repeated Cannabidiol Treatment in Teenagers With Social Anxiety Disorders
Masataka, N. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.02466 · Cited by 157 · see citing works
Buckner, J. D., Heimberg, R. G., Ecker, A. H., & Vinci, C. (2013) · Depression and Anxiety · doi:10.1002/da.22032 · Cited by 181 · see citing works
Medicinal plants with potential anti-arthritic activity:
Choudhary, M., Kumar, V., Malhotra, H., & Singh, S. (2015) · Journal of Intercultural Ethnopharmacology · doi:10.5455/jice.20150313021918 · Cited by 185 · see citing works
Gomes, F. V., Resstel, L. B. M., & Guimarães, F. S. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2036-z · Cited by 174 · see citing works
Cannabidiol (CBD) use in psychiatric disorders: A systematic review
Bonaccorso, S., Ricciardi, A., Zangani, C., Chiappini, S., & Schifano, F. (2019) · NeuroToxicology · doi:10.1016/j.neuro.2019.08.002 · Cited by 170 · see citing works
Anxiolytic-like effect of oxytocin in the simulated public speaking test
de Oliveira, D. C., Zuardi, A. W., Graeff, F. G., Queiroz, R. H., & Crippa, J. A. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111400642 · Cited by 154 · see citing works
Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series
Elms, L., Shannon, S. M., Hughes, S., & Lewis, N. (2018) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2018.0437 · Cited by 156 · see citing works
Sarris, J. J., McIntyre, E., & Camfield, D. (2013) · CNS Drugs · doi:10.1007/s40263-013-0059-9 · Cited by 154 · see citing works
Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug
Schier, A. R. D. M., Ribeiro, N. P. D. O., Silva, A. C. D. O. E., Hallak, J. E. C., Crippa, J. A. S., Nardi, A. E., & Zuardi, A. W. (2012) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462012000500008 · Cited by 154 · see citing works
Fogaça, M. V., Reis, F. M. C. V., Campos, A. C., & Guimarães, F. S. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.012 · Cited by 153 · see citing works
Kicman, A., & Toczek, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186740 · Cited by 154 · see citing works
The Endocannabinoid System of Animals
Silver, R. (2019) · Animals · doi:10.3390/ani9090686 · Cited by 148 · see citing works
Moltke, J., & Hindocha, C. (2021) · Journal of Cannabis Research · doi:10.1186/s42238-021-00061-5 · Cited by 148 · see citing works
Lemos, J. I., Resstel, L. B., & Guimarães, F. S. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.09.045 · Cited by 146 · see citing works
Oxytocin׳s role in anxiety: A critical appraisal
MacDonald, K., & Feifel, D. (2014) · Brain Research · doi:10.1016/j.brainres.2014.01.025 · Cited by 139 · see citing works
Sholler, D. J., Schoene, L., & Spindle, T. R. (2020) · Current Addiction Reports · doi:10.1007/s40429-020-00326-8 · Cited by 143 · see citing works
Wilkinson, S. T., Stefanovics, E., & Rosenheck, R. A. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09475 · Cited by 145 · see citing works
Lee, J. L. C., Bertoglio, L. J., Guimarães, F. S., & Stevenson, C. W. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13724 · Cited by 140 · see citing works
de Faria, S. M., de Morais Fabrício, D., Tumas, V., Castro, P. C., Ponti, M. A., Hallak, J. E., Zuardi, A. W., Crippa, J. A. S., & Chagas, M. H. N. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119895536 · Cited by 140 · see citing works
Freeman, T. P., Morgan, C. J. A., Hindocha, C., Schäfer, G., Das, R., & Curran, H. V. (2014) · Addiction · doi:10.1111/add.12634 · Cited by 140 · see citing works
Lu, K., Gray, M. A., Oliver, C., Liley, D. T., Harrison, B. J., Bartholomeusz, C. F., Phan, K. L., & Nathan, P. J. (2004) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.611 · Cited by 139 · see citing works
Campos, A. C., Ferreira, F. R., & Guimarães, F. S. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.08.012 · Cited by 139 · see citing works
Colizzi, M., & Bhattacharyya, S. (2017) · Current Addiction Reports · doi:10.1007/s40429-017-0142-2 · Cited by 138 · see citing works
Mood, Anxiety, and Serum IGF-1 in Elderly Men Given 24 Weeks of High Resistance Exercise
Cassilhas, R. C., Antunes, H. K. M., Tufik, S., & de Mello, M. T. (2010) · Perceptual and Motor Skills · doi:10.2466/pms.110.1.265-276 · Cited by 137 · see citing works
Marco, E. M. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00063 · Cited by 136 · see citing works
Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers
Babalonis, S. L., Haney, M., Malcolm, R. J., Lofwall, M. R., Votaw, V. R., Sparenborg, S., & WALSH, S. L. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.11.030 · Cited by 136 · see citing works
Schiavon, A. P., Bonato, J. M., Milani, H., Guimarães, F. S., & Weffort de Oliveira, R. M. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.06.017 · Cited by 135 · see citing works
Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress
Childs, E., Lutz, J. A., & de Wit, H. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.03.030 · Cited by 138 · see citing works
A naturalistic examination of the perceived effects of cannabis on negative affect
Cuttler, C., Spradlin, A., & McLaughlin, R. J. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.054 · Cited by 136 · see citing works
Use of cannabidiol in anxiety and anxiety-related disorders
Skelley, J. W., Deas, C. M., Curren, Z., & Ennis, J. (2019) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2019.11.008 · Cited by 137 · see citing works
Fleury-Teixeira, P., Caixeta, F. V., da Silva, L. C. R., Brasil-Neto, J. P., & Malcher‐Lopes, R. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01145 · Cited by 125 · see citing works
Guapo, V. G., Graeff, F. G., Zani, A. C. T., Labate, C. M., dos Reis, R. M., & Del‐Ben, C. M. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.02.007 · Cited by 123 · see citing works
CBD (Cannabidiol) Product Attitudes, Knowledge, and Use Among Young Adults
Wheeler, M., Merten, J. W., Gordon, B. T., & Hamadi, H. Y. (2020) · Substance Use & Misuse · doi:10.1080/10826084.2020.1729201 · Cited by 122 · see citing works
Soares, V. D. P., Campos, A. C., Bortoli, V. C. D., Zangrossi, H., Guimarães, F. S., & Zuardi, A. W. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.05.004 · Cited by 112 · see citing works
Uribe-Mariño, A., Biagioni, A. F., Castiblanco-Urbina, M. A., Twardowschy, A., Salgado-Rohner, C. J., Crippa, J. A. S., Hallak, J. E. C., Zuardi, A. W., & Coimbra, N. C. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.188 · Cited by 111 · see citing works
Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview
Esposito, G., Filippis, D. D., Cirillo, C., Iuvone, T., Capoccia, E., Scuderi, C., Steardo, A., Cuomo, R., & Steardo, L. (2012) · Phytotherapy Research · doi:10.1002/ptr.4781 · Cited by 102 · see citing works
Crippa, J. A. S., Hallak, J. E. C., Machado-de-Sousa, J. P., Queiroz, R. H. C., Bergamaschi, M., Chagas, M. H. N., & Zuardi, A. W. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12018 · Cited by 101 · see citing works
Self-citationIs cannabis treatment for anxiety, mood, and related disorders ready for prime time?
Turna, J., Patterson, B. A., & Ameringen, M. V. (2017) · Depression and Anxiety · doi:10.1002/da.22664 · Cited by 101 · see citing works
Gomes, F. V., Reis, D. G., Alves, F. H., Corrêa, F. M., Guimarães, F. S., & Resstel, L. B. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881110389095 · Cited by 97 · see citing works
Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand
Gulbransen, G., Xu, W., & Arroll, B. (2020) · BJGP Open · doi:10.3399/bjgpopen20x101010 · Cited by 97 · see citing works
A Systematic Review and Meta-Analysis of the Haemodynamic Effects of Cannabidiol
Sultan, S. R., Millar, S. A., England, T. J., & O'Sullivan, S. E. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00081 · Cited by 95 · see citing works
“Overall, there was no relationship between drug dose and the size of the effect on haemodynamics (BP p = 0.81, HR p = 0.97, BF p= 0.97; Figure 6).”
BackgroundInfluentialCannabidiol (CBD) in Cancer Management
O’Brien, K. (2022) · Cancers · doi:10.3390/cancers14040885 · Cited by 90 · see citing works
Appiah‐Kusi, E., Petros, N., Wilson, R. J., Colizzi, M., Bossong, M. G., Valmaggia, L., Mondelli, V., McGuire, P. K., & Bhattacharyya, S. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05442-6 · Cited by 93 · see citing works
Campos, A. C., Brant, F., de Miranda, A. S., Machado, F. S., & Teixeira, A. L. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.12.051 · Cited by 93 · see citing works
Hsiao, Y.-T., Yi, P.-L., Li, C.-L., & Chang, F.-C. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.013 · Cited by 91 · see citing works
Ayahuasca Improves Self-perception of Speech Performance in Subjects With Social Anxiety Disorder
SANTOS, R. G. D., Osório, F. D. L., Rocha, J. M., Rossi, G. N., Bouso, J. C., Rodrigues, L. S., Silveira, G. D. O., Yonamine, M., & Hallak, J. E. C. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001428 · Cited by 91 · see citing works
The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence
Arnold, J. C., McCartney, D., Suraev, A. S., & McGregor, I. S. (2022) · Clinical and Translational Science · doi:10.1111/cts.13425 · Cited by 90 · see citing works
de Almeida, V., Levin, R. R., Peres, F. F., Niigaki, S. T., Calzavara, M. B., Zuardi, A. W., Hallak, J. E. C., Crippa, J. A. S., & Abílio, V. C. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.024 · Cited by 90 · see citing works
Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease
Silvestro, S., Schepici, G., Bramanti, P., & Mazzon, E. (2020) · Molecules · doi:10.3390/molecules25215186 · Cited by 90 · see citing works
Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze
Guimarães, F. S., Aguiar, J. C. D., Mechoulam, R., & Breuer, A. (1994) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(94)90027-2 · Cited by 89 · see citing works
Réus, G. Z., Stringari, R. B., Ribeiro, K. F., Luft, T., Abelaira, H. M., Fries, G. R., Aguiar, B. W., Kapczinski, F., Hallak, J. E., Zuardi, A. W., et al. (2011) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2011.00579.x · Cited by 86 · see citing works
Social anxiety and cannabis use: An analysis from ecological momentary assessment
Buckner, J. D., Crosby, R. D., Wonderlich, S. A., & Schmidt, N. B. (2012) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2011.12.006 · Cited by 86 · see citing works
Garcia-Leal, C., Parente, A. C. B. V., Del‐Ben, C. M., Guimarães, F. S., Moreira, A. C., Elias, L. L. K., & Graeff, F. G. (2005) · Psychiatry Research · doi:10.1016/j.psychres.2004.04.010 · Cited by 87 · see citing works
Uso terapêutico dos canabinoides em psiquiatria
Crippa, J. A. S., Zuardi, A. W., & Hallak, J. E. C. (2010) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462010000500009 · Cited by 85 · see citing works
Wright, M., Ciano, P. D., & Brands, B. (2020) · Cannabis and Cannabinoid Research · doi:10.1089/can.2019.0052 · Cited by 85 · see citing works
Valvassori, S. S., Elias, G., de Souza, B., Petronilho, F., Dal-Pizzol, F., Kapczinski, F., Trzesniak, C., Tumas, V., Dursun, S., Nisihara Chagas, M. H., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881109106925 · Cited by 80 · see citing works
Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?
Zlebnik, N. E., & Cheer, J. F. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014038 · Cited by 79 · see citing works
Human Studies of Cannabinoids and Medicinal Cannabis
Robson, P. (2005) · Springer eBooks · doi:10.1007/3-540-26573-2_25 · Cited by 76 · see citing works
Rock, E. M., Limebeer, C. L., Petrie, G. N., Williams, L. A., Mechoulam, R., & Parker, L. A. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4626-5 · Cited by 74 · see citing works
Flack, N., Colwell, M., Drown, C., & Faulk, C. D. (2021) · Clinical Epigenetics · doi:10.1186/s13148-020-00993-4 · Cited by 72 · see citing works
McCartney, D., Benson, M. J., Desbrow, B., Irwin, C. G., Suraev, A. S., & McGregor, I. S. (2020) · Sports Medicine - Open · doi:10.1186/s40798-020-00251-0 · Cited by 75 · see citing works
Pharmacology of human experimental anxiety
Graeff, F. G., Parente, A., Del-Ben, C. M., & Guimarães, F. S. (2003) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2003000400003 · Cited by 70 · see citing works
“(31) Clomipramine 25 0 + 0 Guimarães et al.”
The effects of cannabidiol on persecutory ideation and anxiety in a high trait paranoid group
Hundal, H., Lister, R., Evans, N., Antley, A., Englund, A., Murray, R. M., Freeman, D. H., & Morrison, P. D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117737400 · Cited by 70 · see citing works
Current application of cannabidiol (CBD) in the management and treatment of neurological disorders
Fiani, B., Sarhadi, K. J., Soula, M., Zafar, A., & Quadri, S. A. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04514-2 · Cited by 70 · see citing works
- Authors
- Zuardi, A. W., Cosme, R. A., Graeff, F. G., & Guimarães, F. S.
- Affiliations
- Universidade de São Paulo (BR)
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 1993-01
- Volume
- 7
- Issue
- 1_suppl
- Pages
- 82-88
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W1696206979
- Cited by
- 364
- References
- 39
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 33 · 2023: 28 · 2022: 37 · 2021: 28 · 2020: 43 · 2019: 25 · 2018: 11 · 2017: 21 · 2016: 12 · 2015: 12 · 2014: 9 · 2013: 10 · 2012: 17
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- ipsapirone, cannabidiol, diazepam, anxiety, anxiolytic effects, stress response, blood pressure, sedation, healthy volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
